Search
Search
About
Log in
Join
Experiences with
Acute leukaemia
Posts
Communities
2,764 public posts
Filter results
SCT while feeling well
I have been put forward for a SCT, providing a further heart scan is ok. I have Post ET Myelofibrosis, MPL positive, I also have another mutation, which I’ve been told will increase my chances of getting leukaemia. I have pretty much decided I will go through with it, but know it will be very tough.
I have been put forward for a SCT, providing a further heart scan is ok. I have Post ET Myelofibrosis, MPL positive, I also have another mutation, which I’ve been told will increase my chances of getting leukaemia. I have pretty much decided I will go through with it, but know it will be very tough.
SRH55
in
MPN Voice
1 year ago
Interesting
Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera Review of studies published in Frontiers in Oncology highlights dosing considerations that may help more patients achieve earlier complete hematological response
Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera Review of studies published in Frontiers in Oncology highlights dosing considerations that may help more patients achieve earlier complete hematological response
wateron
in
MPN Voice
1 year ago
New and Emerging Treatments for Newly Diagnosed and R/R CLL/SLL: Targeted Inhibitors - Dr. Susan O'Brien
This webcast on new and emerging treatments for newly diagnosed and R/R CLL/SLL with a focus on targeted inhibitors, presented by Dr. Susan O'Brien is intended for medical professionals and uses moderate "Med-Speak." So only recommended for those accustomed to the medical language. But if you can follow
This webcast on new and emerging treatments for newly diagnosed and R/R CLL/SLL with a focus on targeted inhibitors, presented by Dr. Susan O'Brien is intended for medical professionals and uses moderate "Med-Speak." So only recommended for those accustomed to the medical language. But if you can follow
lankisterguy
Volunteer
in
CLL Support
1 year ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Essential Thrombocythaemia and Pneumococcal vaccine safe to take?
hello my husband is 36 with Essential Thrombocythaemia Calr type 1 and on aspirin only he has received a letter for the Pneumococcal vaccine but I’m wondering is it safe to take with having ET?
hello my husband is 36 with Essential Thrombocythaemia Calr type 1 and on aspirin only he has received a letter for the Pneumococcal vaccine but I’m wondering is it safe to take with having ET?
Green1988
in
MPN Voice
1 year ago
Upcoming Events of Interest
[i]Just received an announcement from our friends at MPN Advocacy & Education International of some interesting upcoming events. [/i] [u]
Webinars
[/u] A Conversation with an MPN Specialist: Everything You Should Know About Clinical Trials Tuesday, February 28, 2023 1:30 - 3:00 pm EST
[i]Just received an announcement from our friends at MPN Advocacy & Education International of some interesting upcoming events. [/i] [u]
Webinars
[/u] A Conversation with an MPN Specialist: Everything You Should Know About Clinical Trials Tuesday, February 28, 2023 1:30 - 3:00 pm EST
hunter5582
in
MPN Voice
1 year ago
APS - Increased Risk of Blood Clots
Has anyone with an MPN with JAK-2 had an Extended Antiphospholipid Profile done? These blood tests check your antibodies (immunoglobulin) which are protective proteins (made by your plasma cells - WBC) produced by your immune system. They attach to foreign substances (antigens) such as bacteria, fungi
Has anyone with an MPN with JAK-2 had an Extended Antiphospholipid Profile done? These blood tests check your antibodies (immunoglobulin) which are protective proteins (made by your plasma cells - WBC) produced by your immune system. They attach to foreign substances (antigens) such as bacteria, fungi
Buggerbear
in
MPN Voice
1 year ago
Allogenic Stem Cell Transplant
I [i]received a Stem cell transplant six months ago. My decision was based on the availability of a suitable donor and being able to get to remission through aggressive chemotherapy. Other treatments had no effect on my rapidly growing leukemia. As of today I’m still in remission, showing 97% chimerism
I [i]received a Stem cell transplant six months ago. My decision was based on the availability of a suitable donor and being able to get to remission through aggressive chemotherapy. Other treatments had no effect on my rapidly growing leukemia. As of today I’m still in remission, showing 97% chimerism
GarciaB
in
MPN Voice
1 year ago
BTK Inhibitor Therapy for CLL: An International Perspective - Stephan Stilgenbauer, MD
BTK Inhibitor Therapy for CLL: An International Perspective Stephan Stilgenbauer, MD Expert Commentary ClinicalThought™ - Targeted therapies, including BTK inhibitors and combinations incorporating BCL-2 inhibitors, have replaced chemoimmunotherapy as the standard of care for treating CLL.
BTK Inhibitor Therapy for CLL: An International Perspective Stephan Stilgenbauer, MD Expert Commentary ClinicalThought™ - Targeted therapies, including BTK inhibitors and combinations incorporating BCL-2 inhibitors, have replaced chemoimmunotherapy as the standard of care for treating CLL.
lankisterguy
Volunteer
in
CLL Support
1 year ago
Doctor mentioned Richters???
I am on the Bruin trial and was randomized to Arm B which is Idelalisib and Rituximab ( 6 months of infusions ). My bloodwork so far has shown slight improvement since the start in January of this year. Now at my last blood work and appointment the doctor has noticed some lymph nodes increasing in size
I am on the Bruin trial and was randomized to Arm B which is Idelalisib and Rituximab ( 6 months of infusions ). My bloodwork so far has shown slight improvement since the start in January of this year. Now at my last blood work and appointment the doctor has noticed some lymph nodes increasing in size
rcusher
in
CLL Support
1 year ago
Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patient with High Risk CLL Who Have Been on Ibrutinib More Than a Year
This is something that some of our USA members have discussed with their doctors and it looks like the logic is correct. [i]"Patients (pts) receiving ibrutinib (ibr) for CLL rarely achieve complete remission (CR) with undetectable minimal residual disease (U-MRD). Therefore, indefinite ibr maintenance
This is something that some of our USA members have discussed with their doctors and it looks like the logic is correct. [i]"Patients (pts) receiving ibrutinib (ibr) for CLL rarely achieve complete remission (CR) with undetectable minimal residual disease (U-MRD). Therefore, indefinite ibr maintenance
Jm954
Administrator
in
CLL Support
1 year ago
BTK Degrader Shows Potential for Treating Refractory CLL and SLL
A novel Bruton's tyrosine kinase (BTK) degrader, NX-2127, has shown potential for treating patients with double- and triple-refractory CLL or SLL who have experienced disease progression while on any covalent or non-covalent BTK inhibitor, as well as a BCL2 inhibitor. NX-2127 a BTK degrader has a novel
A novel Bruton's tyrosine kinase (BTK) degrader, NX-2127, has shown potential for treating patients with double- and triple-refractory CLL or SLL who have experienced disease progression while on any covalent or non-covalent BTK inhibitor, as well as a BCL2 inhibitor. NX-2127 a BTK degrader has a novel
Jm954
Administrator
in
CLL Support
1 year ago
JAK2V617F Allele Burden in Polycythemia Vera: Burden of Proof
Polycythemia vera (PV) is a hematopoietic stem cell (HSC) neoplasm defined by activating somatic mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells, platelets, and neutrophils; significant burden of disease-specific symptoms; high rates of vascular events; and
Polycythemia vera (PV) is a hematopoietic stem cell (HSC) neoplasm defined by activating somatic mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells, platelets, and neutrophils; significant burden of disease-specific symptoms; high rates of vascular events; and
Manouche
in
MPN Voice
1 year ago
CLL Webinar
Hi all Here is the link for today's CLL webinar. This educational webinar will give an overview of how CLL is treated today and the significance of ’hot topics’ and key treatment development advances published and discussed at 2022 international hematology conferences. What is new and what does this
Hi all Here is the link for today's CLL webinar. This educational webinar will give an overview of how CLL is treated today and the significance of ’hot topics’ and key treatment development advances published and discussed at 2022 international hematology conferences. What is new and what does this
Irishcll
in
CLL Support
1 year ago
LLS.ORG (USA) WHAT ARE YOUR TOP PRIORITIES FOR 2023?
Dear Advocate, Whether it’s making sure every patient can afford health insurance that works for them or advancing better treatments, LLS is committed to working tirelessly to advance policies that serve the needs of blood cancer patients and their families. In 2023 we will continue to work closely
Dear Advocate, Whether it’s making sure every patient can afford health insurance that works for them or advancing better treatments, LLS is committed to working tirelessly to advance policies that serve the needs of blood cancer patients and their families. In 2023 we will continue to work closely
lankisterguy
Volunteer
in
CLL Support
1 year ago
Diagnosis: "Favors Essential Thrombocythemia"
So this is good news. Except for one thing. My bmb did show some "mild to moderate reticulin fibrosis. Nevertheless the diagnosis favors the ET. My hematologist says that we will keep a close eye on bloodwork going forward. As I have the Calr 1 mutation and am already on Eliquis, no additional medication
So this is good news. Except for one thing. My bmb did show some "mild to moderate reticulin fibrosis. Nevertheless the diagnosis favors the ET. My hematologist says that we will keep a close eye on bloodwork going forward. As I have the Calr 1 mutation and am already on Eliquis, no additional medication
Mtnlife
in
MPN Voice
1 year ago
Drug interactions/conflicts
Hi everyone I am Coeliac and also have Essential Thrombocythemia for which I take Hydroxycarbamide. Amongst the many side effects from HC my regular blood tests have shown me to be borderline anaemic and my regular GP has monitored this for years - checking kidney & liver function, and also on Folate
Hi everyone I am Coeliac and also have Essential Thrombocythemia for which I take Hydroxycarbamide. Amongst the many side effects from HC my regular blood tests have shown me to be borderline anaemic and my regular GP has monitored this for years - checking kidney & liver function, and also on Folate
quanglewangle
in
MPN Voice
1 year ago
Why do we have mutations?
Why do we all have these bone marrow mutations? It cannot all be due to family DNA bad luck. My haemo told me that he is certain that my mutation is due to exposure to Benzene in petroleum products. In effect I have been poisoned by products which were supposed to be safe. Benzene compounds are still
Why do we all have these bone marrow mutations? It cannot all be due to family DNA bad luck. My haemo told me that he is certain that my mutation is due to exposure to Benzene in petroleum products. In effect I have been poisoned by products which were supposed to be safe. Benzene compounds are still
Andrew8
in
MPN Voice
1 year ago
Can anyone figure out my MRD
Can anyone figure out what my MRD ( CLL cells per 10,000) is from this report. Component Your Value Standard Range Interpretation Flow cytometric immunophenotyping performed on the peripheral blood shows a small, dim kappa restricted B-cell population (representing ~98% of B cells, 6% of total
Can anyone figure out what my MRD ( CLL cells per 10,000) is from this report. Component Your Value Standard Range Interpretation Flow cytometric immunophenotyping performed on the peripheral blood shows a small, dim kappa restricted B-cell population (representing ~98% of B cells, 6% of total
johnliston
in
CLL Support
1 year ago
CLL Educational Webinar
This educational webinar will give an overview of how CLL is treated today and the significance of ’hot topics’ and key treatment development advances published and discussed at 2022 international hematology conferences. What is new and what does this mean for patients? We will be joined by: Prof Paolo
This educational webinar will give an overview of how CLL is treated today and the significance of ’hot topics’ and key treatment development advances published and discussed at 2022 international hematology conferences. What is new and what does this mean for patients? We will be joined by: Prof Paolo
Irishcll
in
CLL Support
1 year ago
Ruxolitinib/Pegylated Interferon Alpha 2a Reduces Spleen Length in Myelofibrosis
« Such deep molecular responses, to our knowledge, have never been seen in patients with myelofibrosis before,” Kiladjian noted » »A previously developed mathematical model for predicting long-term responses in patients with PV and ET was found to be applicable to this study and predicted a long-term
« Such deep molecular responses, to our knowledge, have never been seen in patients with myelofibrosis before,” Kiladjian noted » »A previously developed mathematical model for predicting long-term responses in patients with PV and ET was found to be applicable to this study and predicted a long-term
Manouche
in
MPN Voice
1 year ago
1
...
14
15
16
...
100
Next page
10
20
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
CLL Support
1633 results
MPN Voice
791 results
Leukaemia Support
171 results
View top 10 communities
Sort by
Most Relevant
Newest